MET and neoplasm: Moreover, the c-MET amplification locus could be detected in circulating tumor DNA, suggesting that the early initiation of c-MET inhibitors in those patients who respond to anti-EGFR therapies and do not display emergence of KRAS mutations in blood tests during anti-EGFR therapies [72].